Bionovate Competitors

BIIO Stock  USD 0.0001  0.00  0.000003%   
Bionovate Technologies competes with Bullfrog, Kazia Therapeutics, Soligenix, Silo Pharma, and Can Fite; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Bionovate Technologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bionovate Technologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bionovate Technologies Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bionovate Technologies competition on your existing holdings.
At this time, Bionovate Technologies' Return On Capital Employed is very stable compared to the past year. As of the 19th of January 2026, Return On Equity is likely to grow to 0.20, while Return On Tangible Assets are likely to drop (49.49). As of the 19th of January 2026, Net Tangible Assets is likely to grow to about (430.2 K). In addition to that, Return On Tangible Assets is likely to drop to -49.49.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details

Bionovate Technologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bionovate Technologies and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bionovate and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bionovate Technologies does not affect the price movement of the other competitor.

High positive correlations

ENSCCANF
BNBXCANF
ENSCBNBX
CANFMSPR
BNBXSILO
CMNDCANF
  

High negative correlations

CMNDKZIA
KZIAMSPR

Risk-Adjusted Indicators

There is a big difference between Bionovate Stock performing well and Bionovate Technologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bionovate Technologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Bionovate Technologies and related stocks such as MSP Recovery, Bullfrog AI Holdings, and Kazia Therapeutics Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026

Bionovate Technologies and related stocks such as MSP Recovery, Bullfrog AI Holdings, and Kazia Therapeutics Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Bionovate Technologies financial statement analysis. It represents the amount of money remaining after all of Bionovate Technologies Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Bionovate Technologies Competitive Analysis

The better you understand Bionovate Technologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bionovate Technologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bionovate Technologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BIIO MSPR BFRG KZIA SNGX SILO CANF CMND BNBX ENSC
 0.000003 
 0.0001 
Bionovate
 2.90 
 0.07 
MSP
 5.26 
 0.72 
Bullfrog
 2.14 
 7.16 
Kazia
 5.22 
 1.41 
Soligenix
 2.56 
 0.38 
Silo
 6.54 
 4.00 
Can
 4.94 
 2.50 
Clearmind
 2.45 
 1.67 
Applied
 6.67 
 0.84 
Ensysce
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Operating Margin
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Book Value Per Share
Return On Asset
Number Of Shares Shorted
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Bionovate Technologies Competition Performance Charts

Five steps to successful analysis of Bionovate Technologies Competition

Bionovate Technologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bionovate Technologies in relation to its competition. Bionovate Technologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bionovate Technologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bionovate Technologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bionovate Technologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bionovate Technologies position

In addition to having Bionovate Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals ETFs Thematic Idea Now

Precious Metals ETFs
Precious Metals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bionovate Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionovate Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionovate Technologies Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionovate Technologies Corp Stock:
Check out Bionovate Technologies Correlation with its peers.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionovate Technologies. If investors know Bionovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionovate Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionovate Technologies is measured differently than its book value, which is the value of Bionovate that is recorded on the company's balance sheet. Investors also form their own opinion of Bionovate Technologies' value that differs from its market value or its book value, called intrinsic value, which is Bionovate Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionovate Technologies' market value can be influenced by many factors that don't directly affect Bionovate Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionovate Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionovate Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionovate Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.